Applied NeuroSolutions, Inc. ("APNS") is a development stage biopharmaceutical company primarily engaged in the research and development of novel therapeutic targets for the treatment of Alzheimer's disease ("AD") and diagnostics to detect AD.
Alzheimer's disease is the most common cause of dementia among people age 65 and older. Dementia is the loss of memory, reason, judgment and language to such an extent that it interferes with a person's daily life and activities. Currently it is estimated that over five million people in the U.S. have Alzheimer's disease and the national cost of caring for people with Alzheimer's is thought to be $100 billion annually. The market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan), according to BioPortfolio, Ltd.
Alzheimer's disease is the most common cause of dementia among people age 65 and older. Dementia is the loss of memory, reason, judgment and language to such an extent that it interferes with a person's daily life and activities. Currently it is estimated that over five million people in the U.S. have Alzheimer's disease and the national cost of caring for people with Alzheimer's is thought to be $100 billion annually. The market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan), according to BioPortfolio, Ltd.
